Liposome-based drug delivery in breast cancer treatment
Open Access
- 1 June 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 4 (3), 95-99
- https://doi.org/10.1186/bcr432
Abstract
Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels. Liposomal anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs represent an integration of biological components capable of tumor recognition with delivery technologies.Keywords
This publication has 23 references indexed in Scilit:
- Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.2002
- Developing Drugs to Decrease the Toxicity of ChemotherapyJournal of Clinical Oncology, 2001
- Tumor targeting using anti-her2 immunoliposomesJournal of Controlled Release, 2001
- Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast CancerJournal of Clinical Oncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.International Journal of Oncology, 1998
- Immunoliposomes for Cancer TreatmentAdvances in Pharmacology, 1997
- Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in VitroBiochemistry, 1997
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Development of anti-p185HER2 immunoliposomes for cancer therapy.Proceedings of the National Academy of Sciences, 1995